The FDA has declined to approve Arena Pharmaceuticals' weight-loss drug lorcaserin, citing concern about the medicine's potential risks and "minimal" effectiveness.
The agency asked for an independent review of a study demonstrating the growth of breast tumors in female rats treated with lorcaserin. "We will work with the agency to address the issues," CEO Jack Lief said.

Related Summaries